Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses various diagnostic and treatment strategies for canine prostate diseases, including pharmacological options and advanced procedures, but reports no new clinical results.

This review discusses the adverse effects on hair associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for comprehensive documentation of these effects.

This study found that Flightless I (Flii) positively influences hair follicle regeneration in rodents, contrasting with its known negative effect on wound healing.

This study reports that chemotherapy-induced hair loss affects up to 65% of patients, typically within 1 to 3 weeks of treatment, while scalp cooling may help prevent severe hair loss with taxane-based therapies.

This report discusses a potentially underdiagnosed form of multisystem Langerhans cell histiocytosis in infants, demonstrating the use of thymic sonography for staging, highlighting a case where thymic and cutaneous involvement was confirmed, and suggesting thymic ultrasound may aid in better diagnosis and management of LCH.

In this study of pediatric melanocytic lesions, researchers at Massachusetts General Hospital observed no concurrent BAP1 loss and BRAFV600E positivity, characteristics of adult BIMT, suggesting that these tumors may develop at a later age rather than in childhood.

This study found that the survival and proliferation of mouse melanocytes expressing the GNAQQ209L oncogene were impaired by interactions with the epidermal microenvironment, suggesting a possible mechanism for the rarity of these mutations in epidermal melanomas.

This study found that in mice, the epidermal microenvironment reverses the oncogenic effects of GNAQQ209L in melanocytes, inhibiting their survival and proliferation through paracrine signals.

This study found that GNAQQ209L expression in mouse melanocytes led to reduced survival in the interfollicular epidermis due to paracrine signaling, while GNAQQ209L boosted survival in a different microenvironment.

This study observed that nevus melanocytes do not exhibit signs of senescence, suggesting that their growth arrest is due to cell interactions and not directly caused by BRAF activation.

This study suggests that the growth arrest of nevus melanocytes is not due to oncogene-induced senescence but rather to collective cell interactions, similar to those in normal tissue size regulation.

The document concludes that understanding nail anatomy is key for diagnosing nail diseases, early signs of nail melanoma may allow for less aggressive treatment, and specific genetic mutations are important in thyroid cancer prognosis and treatment.

This article reviews the cutaneous reactions associated with targeted cancer therapies and highlights the importance of dermatologists recognizing these reactions to provide effective care but reports no clinical results.

This review discusses the genetic pathways involved in melanoma and suggests that targeting these pathways with pharmacological inhibitors may provide a new therapeutic approach, though clinical results have been disappointing so far.

This study found that scalp melanoma often occurs in areas with androgenetic alopecia, and patients without alopecia might experience a later diagnosis due to hair coverage, leading to potentially worse outcomes.

This study found that scalp melanoma in areas with androgenetic alopecia presents with more frequent detrimental mutations and may have a poorer prognosis due to late diagnosis linked to hair concealment.

In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.

This review discusses recent developments in targeted melanoma therapies, including BRAF/MEK/ERK pathway inhibitors and challenges like resistance and skin toxicities, but reports no new clinical results.

RET mutation is important in familial medullary thyroid carcinoma, and BRAF mutation in papillary thyroid carcinoma is linked to more aggressive cancer and higher death rates.

This study found that among melanoma patients in a real-world setting, adjuvant anti-PD-1 antibodies and BRAF/MEK inhibitors were associated with a recurrence-free survival of 78.1% and 86.5% respectively after 12 months.

This study suggests that melanoma tumor cells exhibit intrinsic plasticity, challenging the applicability of the cancer stem cell model to this malignancy.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

Immune cells boost stem cell activity in hairy moles, causing more hair growth.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

This review synthesizes current evidence on the Warburg effect in anaplastic thyroid carcinoma and discusses potential therapeutic targets, but reports no new clinical results.

This narrative review highlights the potential of naturally occurring compounds to target specific molecular pathways and overcome resistance in advanced and recurrent papillary thyroid cancer, offering new therapeutic possibilities beyond traditional treatments like surgery and lifelong hormone replacement.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

This study highlights that biological therapy, which stimulates the immune system through various methods like cytokine injections and immune checkpoint inhibition, shows promise for treating melanoma based on laboratory and clinical studies.

Non-scarring hair loss can be diagnosed with two 4mm punch biopsies, one cut vertically and the other transversely.

This study suggests that caveolin-1 may be a potential target for treating psoriasis, as its downregulation was linked to psoriasis markers that improved with soluble caveolin scaffolding domain peptide treatment.